Volatile Organic Compounds (VOCs) are chemicals that vaporise at room temperature and can be present in pharmaceutical products, cosmetics, packaging materials and indoor air. On the pharmaceutical side, the dominant workload is residual solvent testing per ICH Q3C(R8) and the compendial general chapter USP <467>. Auriga Research offers NABL-accredited VOC and residual solvent testing across Delhi, Baddi and Bangalore on validated GC headspace (GC-HS) and GC-MS platforms — covering all three Q3C(R8) solvent classes, the OVI compendial procedures and the CDSCO 2 ppm benzene workflow.
What is VOC Testing?
VOC testing is the laboratory analysis of volatile organic compounds that can be released from products, raw materials, adhesives, coatings and consumer goods. It is widely used to screen for solvent residues, odour-causing chemicals, toxic air pollutants and volatile impurities that affect product quality and exposure risk. For pharma, VOC analysis is most often residual solvent testing on APIs, intermediates, excipients and finished dosage forms.
Common Volatile Organic Compounds
- Acetone — found in nail polish remover, wallpaper and furniture polish.
- Benzene — traced to candles, stoves, cigarettes and certain solvent-based products; regulated in pharma by the CDSCO 2 ppm notification limit.
- Carbon disulfide — an industrial solvent (viscose rayon, cellophane and cellulose xanthation, rubber vulcanisation, certain agrochemical syntheses), with natural geological background (volcanic emissions, marshes) and trace formation in some chemical synthesis pathways. Not a chlorinated-tap-water byproduct.
- Dichlorobenzene — commonly detected in mothballs and air fresheners.
- Ethanol — used in glass cleaners, dishwasher detergents and laundry products; common Class 3 solvent in pharma.
- Formaldehyde — emitted from floor lacquers, resins and some plastics.
- Terpenes — present in fragrant soaps, detergents and scented consumer products.
- Toluene — a Class 2 solvent and common solvent in paints, coatings and adhesives.
- Xylene — found in traffic emissions, paint thinners and solvent blends.
Pharmaceutical Applications — Residual Solvents per ICH Q3C(R8) & USP <467>
Residual solvents are governed by ICH Q3C(R8) — Impurities: Guideline for Residual Solvents, which classifies solvents into three risk-based classes with corresponding control strategies, and by the compendial general chapter USP <467> (with harmonised counterparts in EP 2.4.24 and IP), which prescribes the test procedure.
Known human carcinogens or environmentally hazardous solvents — to be avoided in production. Includes benzene, carbon tetrachloride, 1,2-dichloroethane, 1,1-dichloroethene and 1,1,1-trichloroethane. Strict ppm-level concentration limits apply.
Solvents associated with non-genotoxic animal carcinogenicity or other significant but reversible toxicity — usage limited by PDE values. Includes acetonitrile, chloroform, dichloromethane, methanol, hexane, toluene, dimethylformamide and 2-methoxyethanol.
Solvents with low toxic potential; PDE of 50 mg/day or more is considered acceptable without further justification. Includes acetone, ethanol, ethyl acetate, butyl acetate, isopropanol (IPA), n-pentane and methyl ethyl ketone.
How GC Headspace Is Used for Residual Solvent Testing
Auriga Research performs residual solvent testing on a validated GC headspace (GC-HS) platform — the standard sample-introduction technique prescribed by USP <467> for low-volatility matrices like APIs and tablets. The sample is sealed in a glass vial with a high-boiling-point diluent (typically DMSO, DMI or water depending on the API), thermostatted to drive volatile solvents into the headspace, and a fixed-volume vapour aliquot is then injected onto the GC column. Detection is by FID for general profiling or by MS for confirmation of identity and trace-level work.
- Validated to ICH Q2(R2) & USP <467> — system suitability, linearity, precision, accuracy, LOD/LOQ at Q3C(R8) PDE thresholds.
- USP <467> Procedure A / B / C workflow — Procedure A for Class 1 + Class 2 screening, Procedure B confirmation on an orthogonal column, Procedure C for quantitative limit testing.
- Q3C(R8) ppm reporting — results reported against the option 1 (concentration limit) or option 2 (PDE / max daily dose) criterion stated in the client specification.
- API, excipient and finished-product matrices — including release testing for tablets, capsules, sterile injectables, ointments and inhalation products.